Correction of Cardiac Abnormalities in Fabry Mice by Direct Intraventricular Injection of a Recombinant Lentiviral Vector That Engineers Expression of .ALPHA.-Galactosidase A

Abstract

A localized benefit of directly injecting a therapeutic LV into the heart has been shown, confirming the utility of this delivery system for research and therapy for a variety of cardiovascular disorders.